

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUAVPPPMB

Page 1 of 2

DOCTOR'S O	RDERS	Htc	n Wt	kg BSA	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form						
DATE:	To be give	en:	C	Cycle #:		
Date of Previous Cycle	e:					
☐ Delay treatment _ ☐ CBC & Diff day of						
109/L, platelets great	netrexed, CARBOplatin, CISpla <u>er than or equal to</u> 100 x 10 ⁹ / netrexed and CARBOplatin) , o	L, and creatinine	clearance grea	ater than or equal to	<u>)</u>	
May proceed with pembrolizumab as written if within 96 hours creatinine <u>less than or equal to</u> 1.5 times the upper limit of normal <u>and less than or equal to</u> 1.5 times the baseline, ALT <u>less than or equal to</u> 3 times the upper limit of normal, <u>bilirubin less than or equal to</u> 1.5 times the upper limit of normal						
Dose modification for: Proceed with treatme	☐ Hematology ent based on blood work fro		ner Toxicity: _			
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm						
dexamethasone						
	aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and ondansetron 8 mg PO 30 to 60 minutes prior to treatment					
	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment					
ondansetron 8 mg PO 30 to 60 minutes prior to treatment						
If additional antiemetic required: ☐ OLANZapine ☐ 2.5 mg or ☐ 5 mg or ☐ 10 mg (select one) PO 30 to 60 minutes prior to treatment						
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose.						
acetaminophen 32	tion: E 50 mg PO 30 minutes prior to 25 to 975 mg PO 30 minutes p 5 mg IV 30 minutes prior to tre	orior to treatment				
Have Hypersensitivity Reaction Tray & Protocol Available						
HYDRATION:						
1000 mL NS over 1 ho	our prior to CISplatin					
Continued on page 2						
DOCTOR'S SIGNA	TURE:			SIGNATURE:		
				UC:		



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LUAVPPPMB

Page 2 of 2

DATE:					
TREATMENT:					
pembrolizumab 2 mg/kg x kg = mg (max. 200 mg)					
IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter					
pemetrexed 500 mg/m² x BSA = mg Dose Modification:% = mg/m² x BSA = mg IV in 100 mL NS over 10 minutes (may be given during prehydration) Select one: CISplatin 75 mg/m² x BSA = mg					
Dose Modification: % = mg/m² x BSA = mg	::t-1 20				
IV in 500 mL NS, with potassium chloride 20 mEq, magnesium sulphate 1 g and manr OR	nitoi 30 g over 1 nour				
☐ CARBOplatin AUC 5 x (GFR + 25) = mg IV in 100 to 250 mL NS over	30 minutes				
RETURN APPOINTMENT ORDERS					
Return in three weeks for Doctor and Cycle Last Cycle. Return in week(s)					
CBC & Diff, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH prior to each treatment					
Vitamin B12 injection required every 9 weeks. Patient to obtain supply.					
☐ This patient to receive injection in clinic. Next injection due by					
If clinically indicated: ECG Chest X-ray					
serum HCG or urine HCG (select one) – required for woman of child bearing potential					
☐ Free T3 and free T4 ☐ lipase ☐ morning serum cortisol ☐ Glucose					
☐ serum ACTH levels ☐ testosterone ☐ estradiol ☐ FSH ☐ LH					
□ Weekly nursing assessment					
☐ Other consults					
☐ See general orders sheet for additional requests.					
DOCTOR'S SIGNATURE:	SIGNATURE:				
	UC:				